49 related articles for article (PubMed ID: 38433845)
1. Tumor Mutational Burden from Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance: An Emerging Biomarker for Surveillance.
Wehrle CJ; Hong H; Kamath S; Schlegel A; Fujiki M; Hashimoto K; Kwon DCH; Miller C; Walsh RM; Aucejo F
Ann Surg; 2024 Jun; ():. PubMed ID: 38860385
[TBL] [Abstract][Full Text] [Related]
2. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.
Lin KY; Zhang JX; Lin ZW; Chen QJ; Luo LP; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Li JD; Wang K; Zheng L; Zheng SM; Wu MM; Lin KC; Yang T; Zeng YY
Front Immunol; 2024; 15():1308543. PubMed ID: 38433845
[TBL] [Abstract][Full Text] [Related]
3. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
4. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Lin KY; Lin ZW; Chen QJ; Luo LP; Zhang JX; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Zhang JY; You WY; Wang B; You PH; Lin KC; Yang T; Zeng YY
Hepatol Int; 2023 Dec; 17(6):1477-1489. PubMed ID: 37382760
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.
An SL; Xiao T; Wang LM; Rong WQ; Wu F; Feng L; Liu FQ; Tian F; Wu JX
Asian Pac J Cancer Prev; 2015; 16(10):4421-7. PubMed ID: 26028108
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.
Lin KY; Chen QJ; Tang SC; Lin ZW; Zhang JX; Zheng SM; Li YT; Wang XM; Lu Q; Fu J; Guo LB; Zheng LF; You PH; Wu MM; Lin KC; Zhou WP; Yang T; Zeng YY
BMC Cancer; 2023 Dec; 23(1):1190. PubMed ID: 38053048
[TBL] [Abstract][Full Text] [Related]
7. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
8. Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Cao Y; Tang H; Hu B; Zhang W; Wan T; Han J; Jiao T; Li J; Li X; Yang Z; Liu Z; Hu M; Duan W; Li C; Zhao Z; Lu S
HPB (Oxford); 2023 Jul; 25(7):775-787. PubMed ID: 36973160
[TBL] [Abstract][Full Text] [Related]
9. Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.
Merino M; Kasamon Y; Theoret M; Pazdur R; Kluetz P; Gormley N
J Clin Oncol; 2023 May; 41(15):2706-2712. PubMed ID: 36930853
[No Abstract] [Full Text] [Related]
10. Breakthroughs in Hepatocellular Carcinoma Therapies.
Singal AG; Kudo M; Bruix J
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2135-2149. PubMed ID: 36813012
[TBL] [Abstract][Full Text] [Related]
11. Management of Hepatocellular Carcinoma: A Review.
Brown ZJ; Tsilimigras DI; Ruff SM; Mohseni A; Kamel IR; Cloyd JM; Pawlik TM
JAMA Surg; 2023 Apr; 158(4):410-420. PubMed ID: 36790767
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
[TBL] [Abstract][Full Text] [Related]
13. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD; Huang C; Shen YH; Xu B; Ge NL; Ji Y; Qu XD; Chen L; Chen Y; Li ML; Zhu JJ; Tang ZY; Zhou J; Fan J; Sun HC
Ann Surg Oncol; 2023 May; 30(5):2782-2790. PubMed ID: 36178565
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
